In summary, HDAC7 is increased in the astrocytes of AD patients and PS19 mice, and it could induce AD-like tau pathologies via deacetylating TFEB and inhibiting lysosomal biogenesis in astrocytes. Here, MAPT is linked to Alzheimer disease.